David C. Limburg
Pfizer (United States)(US)
Publications by Year
Research Areas
Signaling Pathways in Disease, Peptidase Inhibition and Analysis, Toxin Mechanisms and Immunotoxins, Catalytic C–H Functionalization Methods, Cytokine Signaling Pathways and Interactions
Most-Cited Works
- → The novel benzopyran class of selective cyclooxygenase-2 inhibitors. Part 2: The second clinical candidate having a shorter and favorable human half-life(2010)326 cited
- → Dual Inhibition of TYK2 and JAK1 for the Treatment of Autoimmune Diseases: Discovery of (( S )-2,2-Difluorocyclopropyl)((1 R ,5 S )-3-(2-((1-methyl-1 H -pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841)(2018)170 cited
- → 1-Cyanoimidazole as a Mild and Efficient Electrophilic Cyanating Agent(2000)94 cited
- → Covalent Inhibitors of Interleukin-2 Inducible T Cell Kinase (Itk) with Nanomolar Potency in a Whole-Blood Assay(2012)78 cited
- → A mild deprotection procedure for tert-butyl esters and tert-butyl ethers using ZnBr2 in methylene chloride(2000)64 cited
- → Selective inducible microsomal prostaglandin E2 synthase-1 (mPGES-1) inhibitors derived from an oxicam template(2010)61 cited
- → Synthesis of N-Glyoxyl Prolyl and Pipecolyl Amides and Thioesters and Evaluation of Their In Vitro and In Vivo Nerve Regenerative Effects(2002)52 cited
- → Automated Nanomole-Scale Reaction Screening toward Benzoate Bioisosteres: A Photocatalyzed Approach to Highly Elaborated Bicyclo[1.1.1]Pentanes(2021)43 cited
- → The novel benzopyran class of selective cyclooxygenase-2 inhibitors. Part III: The three microdose candidates(2010)36 cited
- → Formation of nitrogen‐containing heterocycles using di(imidazole‐1‐yl)methanimine(2003)34 cited